Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates [Yahoo! Finance]
Entrada Therapeutics, Inc. (TRDA)
Company Research
Source: Yahoo! Finance
Revenue and earnings per share (EPS) forecasts were both revised downwards, with the analysts seeing grey clouds on the horizon. Shares are up 5.5% to US$12.41 in the past week. It will be interesting to see if this downgrade motivates investors to start selling their holdings. Following the downgrade, the consensus from four analysts covering Entrada Therapeutics is for revenues of US$45m in 2024, implying a stressful 65% decline in sales compared to the last 12 months. Per-share losses are expected to explode, reaching US$3.01 per share. However, before this estimates update, the consensus had been expecting revenues of US$58m and US$2.10 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase. See our latest analysis for Entrada Therapeutics Looking at the bigger picture now, one of the ways we can make sense of these
Show less
Read more
Impact Snapshot
Event Time:
TRDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRDA alerts
High impacting Entrada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRDA
News
- The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc.PR Web
- Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire
- Entrada Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Entrada Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswire
TRDA
Earnings
- 3/13/24 - Miss
TRDA
Analyst Actions
- 3/18/24 - HC Wainwright
TRDA
Sec Filings
- 4/26/24 - Form 144
- 4/25/24 - Form 144
- 4/24/24 - Form 144
- TRDA's page on the SEC website